Major breakthrough in hepatitis C vaccine development
Researchers at the Burnet Institute have solved a hepatitis C vaccine mystery which, once developed, could be the first ever preventative vaccine for the virus.
Hepatitis C affects around 200 million people around the world, so a preventative vaccine has the potential to have a significant global health impact.
Currently undergoing formal preclinical studies, the vaccine is the result of breakthrough work done by Associate Professor Heidi Drummer with her team from the Institute’s Centre for Virology.
The team has overcome a major hurdle in HCV vaccine research, developing a vaccine candidate that protects against a number of different HCV strains.
“Hepatitis C has a great ability to change its structure and evade the immune response. This makes vaccine development challenging,” Associate Professor Drummer said.
“Our vaccine is unique as it contains only the most essential, conserved parts of the major viral surface protein, eliciting antibodies that prevent both closely and distantly related hepatitis C viruses from entering cells, thereby preventing infection.”
Associate Professor Drummer unveiled the details about her HCV vaccine project at the prestigious Immunotherapeutics and Vaccine Summit (ImVacS) in Cambridge, Massachussets on 13 August.
Flinders works on method to filter nanoplastics from water
Flinders University researchers are working on a method capable of detecting nanoplastics using...
March workshops seek to empower NT flood evacuees
In March, a workshop series will bring together researchers and community members to co-design a...
Colon cancer DNA in blood can guide chemo decisions
A simple blood test could change how doctors decide which patients with colon cancer need...
